These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 882960)

  • 21. Platelet aggregation in human whole blood after chronic administration of aspirin.
    de la Cruz JP; Camara S; Bellido I; Carrasco T; Sanchez de la Cuesta F
    Thromb Res; 1987 Apr; 46(1):133-40. PubMed ID: 3109069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ethanol-inhibited platelet prostaglandin synthesis in vitro.
    Stuart MJ
    J Stud Alcohol; 1979; 40(1):1-6. PubMed ID: 449324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Some characteristics of mouse platelet aggregation and a comparison of the activity of a range of compounds in mouse and human platelet-rich plasma in vitro.
    Nunn B
    Thromb Haemost; 1981 Feb; 45(1):1-5. PubMed ID: 7245119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of thromboxane A2.
    Ambler J; Birch J; Maguire ED; Wallis RB
    Adv Exp Med Biol; 1985; 192():293-308. PubMed ID: 2939695
    [No Abstract]   [Full Text] [Related]  

  • 25. Alpha-tocopherol: its inhibition on human platelet aggregation.
    Fong JS
    Experientia; 1976 May; 32(5):639-41. PubMed ID: 1278322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen.
    Di Minno G; Cerbone A; Usberti M; Cianciaruso B; Cortese A; Farace MJ; Martinez J; Murphy S
    J Lab Clin Med; 1986 Sep; 108(3):246-52. PubMed ID: 3018111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro evaluation of inhibitors of platelet release and aggregation.
    Rosenberg JC; Sell TL
    Arch Surg; 1975 Aug; 110(8):980-3. PubMed ID: 168838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased synthesis of prostaglandin-E-like material by platelets from patients with diabetes mellitus.
    Halushka PV; Lurie D; Colwell JA
    N Engl J Med; 1977 Dec; 297(24):1306-10. PubMed ID: 917087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathways responsible for platelet hypersensitivity in rats with diabetes. I. Streptozocin-induced diabetes.
    Winocour PD; Kinlough-Rathbone RL; Mustard JF
    J Lab Clin Med; 1986 Feb; 107(2):148-53. PubMed ID: 3080538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of strontium chloride on blood platelet function.
    Togna G; Gallozzi S; Caprino L
    Arch Toxicol Suppl; 1989; 13():366-9. PubMed ID: 2505737
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of heparin on platelet aggregation and release and thromboxane A2 production.
    Mohammad SF; Anderson WH; Smith JB; Chuang HY; Mason RG
    Am J Pathol; 1981 Aug; 104(2):132-41. PubMed ID: 7258300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of 8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxy carboxyl methoxy coumarin (AD6) on aggregation, arachidonic acid metabolism and thromboxane B2 formation in human platelets.
    Galli C; Agradi E; Petroni A; Socini A
    Pharmacol Res Commun; 1980 Apr; 12(4):329-37. PubMed ID: 7393988
    [No Abstract]   [Full Text] [Related]  

  • 33. Some properties of rat platelet aggregation and effects of butylated hydroxytoluene, warfarin and aspirin.
    Takahashi O
    Food Chem Toxicol; 1991 Mar; 29(3):173-83. PubMed ID: 1903353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dihomo-gamma-linolenate suppresses platelet aggregation when administered in vitro or in vivo.
    Willis AL; Comai K; Kuhn DC; Paulsrud J
    Prostaglandins; 1974 Dec; 8(6):509-19. PubMed ID: 4462154
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of three nonsteroidal anti-inflammatory agents on platelet function and prostaglandin synthesis in vitro.
    McIntyre BA; Philp RB
    Thromb Res; 1978 Jan; 12(1):67-77. PubMed ID: 644561
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of nitroblue tetrazolium and vitamin E on platelet ultrastructure, aggregation, and secretion.
    White JG; Rao GH; Gerrard JM
    Am J Pathol; 1977 Aug; 88(2):387-402. PubMed ID: 879276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of eicosatetraenyl (3-aminopropyl) phosphonate (URI-73A) on platelet aggregation and arachidonic acid metabolism.
    Mower RL; Landolfi R; Steiner M; Welch DK; Turcotte JG
    Prostaglandins Leukot Med; 1983 Sep; 12(1):95-106. PubMed ID: 6579571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro effect of the coronary vasodilator diltiazem on human and rabbit platelets.
    Shinjo A; Sasaki Y; Inamasu M; Morita T
    Thromb Res; 1978 Dec; 13(6):941-55. PubMed ID: 107614
    [No Abstract]   [Full Text] [Related]  

  • 39. Cadmium-induced platelet hypersensitivity to aggregating agents.
    Caprino L; Togna G; Togna AR
    Pharmacol Res Commun; 1979 Oct; 11(9):731-7. PubMed ID: 231263
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of suprofen, an inhibitor of prostaglandin biosynthesis, on platelet function, plasma coagulation and fibrinolysis. I. In vitro experiments.
    De Clerck F; Vermylen J; Reneman R
    Arch Int Pharmacodyn Ther; 1975 Aug; 216(2):263-79. PubMed ID: 1180617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.